NO961888L - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser - Google Patents

Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser

Info

Publication number
NO961888L
NO961888L NO961888A NO961888A NO961888L NO 961888 L NO961888 L NO 961888L NO 961888 A NO961888 A NO 961888A NO 961888 A NO961888 A NO 961888A NO 961888 L NO961888 L NO 961888L
Authority
NO
Norway
Prior art keywords
inhibitors
therapeutic use
peptidyl compounds
metal proteinases
matrix metalloproteinase
Prior art date
Application number
NO961888A
Other languages
English (en)
Other versions
NO961888D0 (no
Inventor
John Montana
Jonathon Dickens
David Alan Owen
Andrew Douglas Baxter
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of NO961888D0 publication Critical patent/NO961888D0/no
Publication of NO961888L publication Critical patent/NO961888L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelse med formel (l), hvori R1 er Cj^alkyl, C,_ 6alkenyl, aryl, (C^alkyl) aryl eller C^alkyl-AR9 hvor A er O, NR9 eller S(O)m, hvor m = 0-2, og hver R9 er H, C1_4alkyl, aryl eller (C1_4alkyl) -aryl; R2 er H eller Cx_6alkyl; enten er R4 H eller C^.galkyl eventuelt substituert med amino(NH2), aryl- amino, beskyttet amino, aryl, di(C1_6alkyl) amino, 6alkyl)amino, C02H, beskyttet karboksyl, karbamoyl, 6alkyl)karbamoyl eller di (C^.galkyl) -karbamoyl, og R5 er H eller C^alkyl, eller NR4R5 er pyrrolidono, piperidino eller morfolino; R6 er eventuelt substituert C3_6cykloalkyl, C3_6- cykloalkenyl, C1_6alkyl, benzyl, (C1_6alkoksy) benzyl, benzyl- oksybenzyl eller 3-indolylmetyl; Alk er C^.galkyl eller C2_ 5alkenyl, og n = O eller 1; R7 er H eller R10CO hvor R10 er C±_ 4alkyl, (C1_4alkyl)-aryl, C3_6cykloalkyl, (C3_6cykloalkyl) - C1_4alkyl, C2_6alkenyl eller (C2_6alkenyl)aryl; og R8 er H, C^ 4alkyl, (C1_4alkyl)aryl eller aryl; eller et salt, solvat eller hydrat derav. Slike forbindelser kan anvendes for å behandle tilstander i forbindelse med metalloproteinase, TNF og/eller annen aktivitet.
NO961888A 1993-11-10 1996-05-09 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser NO961888L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (2)

Publication Number Publication Date
NO961888D0 NO961888D0 (no) 1996-05-09
NO961888L true NO961888L (no) 1996-05-09

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961888A NO961888L (no) 1993-11-10 1996-05-09 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser

Country Status (22)

Country Link
US (1) US5853623A (no)
EP (1) EP0728144B1 (no)
JP (1) JPH09505041A (no)
KR (1) KR960705843A (no)
CN (1) CN1134705A (no)
AT (1) ATE188969T1 (no)
AU (1) AU679286B2 (no)
BR (1) BR9408025A (no)
CA (1) CA2173470A1 (no)
CZ (1) CZ287780B6 (no)
DE (1) DE69422726T2 (no)
DK (1) DK0728144T3 (no)
ES (1) ES2143611T3 (no)
FI (1) FI961976A (no)
GB (1) GB9323165D0 (no)
GR (1) GR3033103T3 (no)
HK (1) HK1015139A1 (no)
HU (1) HU217344B1 (no)
NO (1) NO961888L (no)
PL (1) PL180403B1 (no)
PT (1) PT728144E (no)
WO (1) WO1995013289A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0715619A4 (en) * 1993-08-23 1997-03-19 Immunex Corp INHIBITORS OF TNF-ALPHA SECRETION
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
EP0784629B1 (en) 1994-10-05 1999-04-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
WO1996035711A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
JPH11504646A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
WO1997012861A1 (en) * 1995-10-05 1997-04-10 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
ATE215946T1 (de) * 1995-11-22 2002-04-15 Darwin Discovery Ltd Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6069150A (en) * 1996-04-04 2000-05-30 F. Hoffman-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
CA2260859A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
AU741903C (en) * 1997-03-03 2002-09-05 Darwin Discovery Limited Selective MMP inhibitors having reduced side-effects
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
ES2206903T3 (es) 1997-03-04 2004-05-16 Monsanto Company Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco.
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
WO1999025687A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
WO2000040552A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. Amidomalonamides and their use as inhibitors of matrix metalloproteinase
US6448250B1 (en) 1999-02-08 2002-09-10 G. D. Searle & Company Sulfamato hydroxamic acid metalloprotease inhibitor
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
JP2003521476A (ja) * 1999-06-15 2003-07-15 メルク エンド カムパニー インコーポレーテッド チオール誘導体、メタロ−β−ラクタマーゼ阻害剤
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
BR0109328A (pt) 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
AU2001245862A1 (en) * 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
BR0109354A (pt) * 2000-03-21 2003-04-15 Procter & Gamble Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
CZ20032913A3 (cs) 2001-05-11 2004-05-12 Pharmaciaácorporation Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
EP1547617B1 (en) * 2002-08-20 2010-04-28 Astellas Pharma Inc. Arthrodial cartilage extracellular matrix degradation inhibitor
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
EP3061460A1 (en) 2009-04-10 2016-08-31 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3774858D1 (de) * 1986-12-24 1992-01-09 Beecham Group Plc Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
PL314300A1 (en) 1996-09-02
FI961976A0 (fi) 1996-05-09
GB9323165D0 (en) 1994-01-05
PT728144E (pt) 2000-07-31
DE69422726T2 (de) 2000-06-08
US5853623A (en) 1998-12-29
NO961888D0 (no) 1996-05-09
DE69422726D1 (de) 2000-02-24
AU679286B2 (en) 1997-06-26
AU8113394A (en) 1995-05-29
CN1134705A (zh) 1996-10-30
JPH09505041A (ja) 1997-05-20
EP0728144B1 (en) 2000-01-19
FI961976A (fi) 1996-05-09
ATE188969T1 (de) 2000-02-15
ES2143611T3 (es) 2000-05-16
CZ287780B6 (en) 2001-02-14
BR9408025A (pt) 1996-12-17
CZ134996A3 (en) 1996-10-16
CA2173470A1 (en) 1995-05-18
DK0728144T3 (da) 2000-07-03
PL180403B1 (pl) 2001-01-31
KR960705843A (ko) 1996-11-08
HU217344B1 (hu) 2002-02-28
WO1995013289A1 (en) 1995-05-18
HU9601244D0 (en) 1996-07-29
EP0728144A1 (en) 1996-08-28
GR3033103T3 (en) 2000-08-31
HUT73799A (en) 1996-09-30
HK1015139A1 (en) 1999-10-08

Similar Documents

Publication Publication Date Title
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
NO971537L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
NZ335981A (en) Ketobenzamides as calpain inhibitors
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
AR019011A1 (es) Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
PT705100E (pt) Guanidinas substituidas terapeuticas
NO982290D0 (no) Merkaptoalkylpeptidyl-forbindelser som har en imidazolsubstituent og deres anvendelse som inhibitorer av matriks-metalloproteinaser (MMP) og/eller tumor nekrosefaktor (TNF)
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
AP9701142A0 (en) 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds.
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
NO972907L (no) 3,3-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
GR920100518A (el) Ενώσεις.
GR920100519A (el) Ενώσεις.
MX9704733A (es) Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application